Prognostic role of CIP2A expression in serous ovarian cancer.
Prognostic role of CIP2A expression in serous ovarian cancer.
复制标题
CIP2A表达在浆液卵巢癌中的预后作用。
DOI：
10.1038/bjc.2011.346
复制
发表时间：
2011-09-27
影响因子：
8.8
通讯作者：
Ristimaki, A.
中科院分区：
文献类型：
--
作者：
Bockelman, C.;Lassus, H.;Hemmes, A.;Leminen, A.;Westermarck, J.;Haglund, C.;Butzow, R.;Ristimaki, A.
蛋白磷酸酶2A（CIP 2A）的癌抑制剂是在几种实体癌中表达的癌蛋白。我们的目的是研究其在浆液性卵巢癌患者中的作用，以及与临床病理变量和分子标志物的相关性。我们回顾性收集了562例连续的浆液性卵巢癌患者在赫尔辛基大学中心医院治疗。我们通过免疫组织化学染色肿瘤组织微阵列的CIP 2A，并根据Kaplan-Meier方法构建存活曲线。通过χ2检验评估与临床病理学和分子标志物的关联。CIP 2A在212例（40.4%）标本中呈强阳性反应，222例（42.4%）标本呈弱阳性反应，90例（17.2%）标本呈阴性反应。免疫阳性CIP 2A表达与高级别（P<0.0001）、晚期（P=0.0005）和非整倍体（P=0.001，χ2检验）相关。蛋白磷酸酶2A过表达的癌抑制因子也与EGFR蛋白表达（P=0.006）和EGFR扩增（P=0.043）相关。卵巢癌患者中强的胞浆CIP 2A免疫阳性预测不良结果（P<0.0001，对数秩检验）。我们的研究结果表明，CIP 2A与卵巢癌患者的生存率降低和与高级别相关的参数相关，因此可能是识别这种疾病的侵袭性亚型（II型）的因素之一。
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein expressed in several solid cancers. Our purpose was to study its role in serous ovarian cancer patients, and the association to clinicopathological variables and molecular markers. We collected retrospectively 562 consecutive serous ovarian cancer patients treated at the Helsinki University Central Hospital. We stained tumour tissue microarrays for CIP2A by immunohistochemistry and constructed survival curves according to the Kaplan–Meier method. Associations to clinicopathological and molecular markers were assessed by the χ2-test. We found strong cytoplasmic CIP2A immunoreactivity in 212 (40.4%) specimens, weak positivity in 222 (42.4%) specimens, and negative in 90 (17.2%). Immunopositive CIP2A expression was associated with high grade (P<0.0001), advanced stage (P=0.0005), and aneuploidy (P=0.001, χ2-test). Cancerous inhibitor of protein phosphatase 2A overexpression was also associated with EGFR protein expression (P=0.006) and EGFR amplification (P=0.043). Strong cytoplasmic CIP2A immunopositivity predicted poor outcome in ovarian cancer patients (P<0.0001, log-rank test). Our results show that CIP2A associates with reduced survival and parameters associated with high grade in ovarian cancer patients, and may thus be one of the factors that identify aggressive subtype (type II) of this disease.
登录
查看更多内容
影响因子：
11.5
作者：
Come, Christophe;Laine, Anni;Westermarck, Jukka
通讯作者：
Westermarck, Jukka
影响因子：
82.9
作者：
Kononen, J;Bubendorf, L;Kallioniemi, OP
通讯作者：
Kallioniemi, OP
影响因子：
254.7
作者：
Parkin, DM;Bray, F;Pisani, P
通讯作者：
Pisani, P
影响因子：
4.7
作者：
Lassus, Heini;Sihto, Harri;Butzow, Ralf
通讯作者：
Butzow, Ralf
影响因子：
11.5
作者：
Erkinheimo, TL;Lassus, H;Ristimäki, A
通讯作者：
Ristimäki, A